FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for ZEMPLAR (paricalcitol) submitted by AbbVie Inc., indicating an approved update to its labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

SUPPL AP for ZEMPLAR (PARICALCITOL)